EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
Pharma's Medical Affairs Bridge: From Field Insights and Stakeholder Needs to Global Scientific Strategy
Medical Affairs has evolved from being primarily a supportive and educational function to becoming a strong strategic partner earlier on Through ongoi...
Advisory Board
.webp "Juris Hmelnickis")
.webp "Eiman Shafa")
KNOWLEDGE BANK
-
Articles
U.S. Pharmaceutical Outsourcing: CRO, CDMO and Contract Manufacturing Strategies
US pharma outsourcing means hiring specialist partners to run parts of drug development and production CROs handle clinical and preclinical research CDMOs handle development and manufacturing Contract manufacturers produce at scale The best strategy matches the partner to your stage risk tolerance and supply chain goals not simply to the lowest bid
-
Techno Trends
Lilly’s Jaypirca Gains FDA Approval for First-Line CLL/SLL Treatment
Eli Lilly and Company has received approval from the US Food and Drug Administration FDA for an additional indication for Jaypirca pirtobrutinib in adults with previously untreated chronic lymphocytic leukaemia CLL or small lymphocytic lymphoma SLL without a known p deletion The approval enables Jaypirca to be used as a firstline treatment
-
Projects
Genentech Begins US$750 Million Expansion of Oregon Manufacturing Facility
Genentech a member of the Roche Group has started construction on a US million expansion of its manufacturing facility in Hillsboro Oregon The squarefoot project will double the existing sites footprint and increase US production capacity for advanced drug delivery devices
-
Research Insights
AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex
The pathohistological hallmarks of Parkinsons disease are aggregated alphasynuclein and other aggregationprone proteins Lewy bodies Recent studies show mechanistic as well as genetic connections between lysosomal dysfunction and Parkinsons disease pathology A direct link between lysosomal function and Parkinsons disease might be the degradation of alphasynuclein within the lysosomal system
-
White Papers
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys complexity
TOP ARTICLES
-
1
Transforming Trials: Modernizing Clinical Research for a Healthier Tomorrow
Kate Williamson
Embracing technological innovations, patient-centric approaches, and regulatory advancements, modernizing clinical trials is revolutionizing healthcare. From decentralized trials and blockchain for tr...
-
2
Building a Sustainable Supply Chain for 2030
Niklas Adamsson
-
3
Closing the Bench-to-Bedside Gap: Biomarker Strategies That Actually De-Risk Development
Lakshmi
Roughly nine out of ten drug candidates that enter clinical testing never reach patients. The failure rate is brutal, and it clusters in the space where laboratory promise meets human biology—th...
-
4
Next-Generation RNA Therapeutics: Expanding the R&D Landscape Beyond Vaccines
Lakshmi
mRNA vaccines proved the chemistry; they did not define the category. Silencing, splicing, editing and in-vivo cell engineering have turned RNA into a mainstream pharmaceutical modality, with roughly...
-
5
How Account-Based Marketing (ABM) Drives Pharma Event Success and Lead Generation
Kate Williamson
Account-Based Marketing (ABM) is transforming pharma event marketing by prioritizing high-value accounts over high-volume leads. This article explores how pharmaceutical companies can use personalized...
press releasesRead more...
Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development
Fortrea a leading global contract research organization CRO and Omico Australias leading precision oncology screening and trial matching organization today announced a collaboration to accelerate precision oncology research by helping connect cancer patients to biomarkermatched clinical trials By co...
Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment
Charles River Laboratories International Inc announced a Research Collaboration Agreement RCA with the US Food and Drug Administration FDA and Labcorp for developing sensitive screening tools to quantify and rank the abuse potential of new drugs including abusedeterrent formulations
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE
BioCryst Pharmaceuticals Inc announced the US Food and Drug Administration FDA has approved its supplemental New Drug Application sNDA for use of the oral pellet formulation of oncedaily ORLADEYO berotralstat for prophylactic therapy in adults and adolescents aged years and older
Radical Numerics Launches Omnii-1, a New Generation of Biological AI, as First AI-Designed Phage Therapy Reaches Human Patient
Radical Numerics an AI research lab building general biological intelligence today launched Omnii a biological AI model that learns across DNA RNA proteins and other molecular data Researchers used Omnii to design a bacteriophage and administered it to a patient with a drugresistant bacterial infect...
Events Read more...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026PM& AC 2026
Novotel Hyderabad Convention C...
28 - 30
Oct 2026BIOPLUS-INTERPHEX Korea
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
LATEST NEWSRead more...
Ignite Proteomics Enters Breast Cancer Research Collaboration with Leading Cancer Center
Ignite Proteomics Inc a precision oncology company focused on functional proteomics today announced it is collaborating with Memorial Sloan Kettering Cancer Center MSK to study protein signaling patterns associated with treatment response and resistance in advanced breast cancer
Warp Sciences Emerges From Stealth With $215 Million to Build U.S. Chemistry Services for Drug Research
Warp Sciences today emerged from stealth with million in funding to create the infrastructure that enables biotech and pharmaceutical companies to discover new medicines faster The company is building a USbased chemistry contract research organization CRO that brings expert chemists
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
Merck known as MSD outside of the United States and Canada today announced the European Commission EC has approved KEYTRUDA pembrolizumab Mercks antiPD therapy in combination with Padcev enfortumab vedotinejfv as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment...
Verily Health and Autoimmune Registry Partner to Build Cross-Disease Research Infrastructure for Autoimmune Conditions
Verily Health Inc a healthcare data intelligence company today announced a strategic partnership with Autoimmune Registry Inc ARI a nonprofit nominated for the inaugural Prix Galien Patient First Award in Honor of Michael J Fox for its work studying autoimmune diseases the populations they affect a...
Jemperli (dostarlimab) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer
GSK plc announced the US Food and Drug Administration FDA has approved Jemperli dostarlimab as the first and only immunotherapy for adults with stage II and III microsatellite instabilityhigh MSIHmismatch repair deficient dMMR locally advanced rectal cancer under the accelerated approval pathway
Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2
Alcon the global leader in eye care dedicated to helping people see brilliantly today announced it has acquired Neurotech Pharmaceuticals Inc a company focused on developing innovative cell therapies for chronic and neurodegenerative eye diseases
